Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17344744 | 0.80 | KDM4E (0.33) | KDM4E | |
| SCHEMBL17026974 | 0.70 | KDM4E (0.35) | KDM4E | |
| SCHEMBL430140 | 0.68 | HSD17B10 (0.50) | KDM4EKMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL13036175 | 0.67 | ADRA2A (0.54) | KDM4EKMT2AHSD17B10MEN1ALOX15 | |
| SCHEMBL17027090 | 0.66 | KDM4E (0.37) | KDM4EALDH1A1 | |
| SCHEMBL12654494 | 0.66 | KDM4E (0.34) | KDM4E | |
| SCHEMBL13543883 | 0.64 | KDM4E (0.39) | KDM4EKMT2AHSD17B10MEN1ALDH1A1 | |
| SCHEMBL17348514 | 0.64 | ADRA2A (0.44) | KDM4EKMT2AHSD17B10MEN1ALOX15 | |
| SCHEMBL1555141 | 0.64 | GAA (0.40) | KDM4EKMT2AHSD17B10MEN1ALDH1A1 | |
| SCHEMBL3586235 | 0.63 | MAPT (0.49) | KDM4EKMT2AHSD17B10MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952503-B1 | CARBOXYLIC ACID DERIVATIVES AS HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | KDM4E 546/4885KMT2A 1031/4885HSD17B10 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.